Results 221 to 230 of about 8,834,434 (252)

Exploring the early impacts of drug decriminalization on harm reduction and opioid agonist treatment service operations and delivery in British Columbia: insights from key informant interviews. [PDF]

BMC Public Health
Russell C, Torres-Salbach S, MacKinnon L, Shahin R, Griffith D, Hodgson K, Burmeister C, Amoraal C, Crichlow F, Imtiaz S, Rehm J, Ali F.   +11 more
europepmc   +1 more source

Do Brain Extracellular Fluid Concentrations Predict PET‐Inferred Receptor Occupancy in Human CNS? A Mechanistic Model‐Based Analysis of Dopamine D2 Receptor Ligands

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1389-1401, November 2026.
A mechanistic CNS PBPK model framework was applied to eight antipsychotic D2 receptor ligands, comparing brain extracellular fluid (brainECF) and brain cell membrane (brainM) as biophase for predicting human receptor occupancy compared against PET neuroimaging data. BrainM concentrations showed improved agreement with PET‐derived receptor occupancy for
Divakar Budda, J.G. Coen van Hasselt, Elizabeth C.M. de Lange   +2 more
wiley   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

The impact of opioid agonist treatment on the incidence of bacterial sexually transmitted infection notifications among people with a history of opioid dependence in New South Wales, Australia: A retrospective data linkage study. [PDF]

Drug Alcohol Depend
Price O, Bharat C, Jones NR, Peacock A, Read P, Hickman M, Degenhardt L.   +6 more
europepmc   +1 more source

First Occurrence of Fatal Intoxication Involving Methiodone (IC‐26) in Finland; a Medicolegal Autopsy Case Report

Drug Testing and Analysis, Volume 18, Issue 11, Page 1486-1489, November 2026.
ABSTRACT Methiodone (IC‐26) is a non‐fentanyl novel synthetic opioid which has recently been detected in drug seizures in Europe. There is still limited data about the drug in published toxicological case work, both in non‐fatal and fatal cases. We present a medicolegal autopsy case report on a fatal intoxication in an individual undergoing opioid ...
Lasse Pakanen, Raimo A. Ketola, Pirkko Kriikku   +2 more
wiley   +1 more source

Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: protocol for a population-based target trial emulation. [PDF]

BMJ Open
Mondol MH, Min JE, Kurz M, Zanette M, Hossain MB, Bach P, Gustafson P, Platt RW, Seaman S, Socías ME, Nosyk B, Karim ME.   +11 more
europepmc   +1 more source

Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study. [PDF]

Harm Reduct J
Panagiotoglou D, Peterson S, Lavergne MR, Gomes T, Chadha R, Johnson C, McCracken R.   +6 more
europepmc   +1 more source

Comparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study. [PDF]

BMJ Open
Kurz M, Guerra-Alejos BC, Hossain MB, Min JE, Yan R, Bruneau J, Catherine NLA, Greenland S, Gustafson P, Hedden L, Karim E, McCandless L, Nolan S, Platt RW, Bach P, Seaman S, Siebert U, Socías ME, Nosyk B.   +18 more
europepmc   +1 more source

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada. [PDF]

Harm Reduct J
Mayer S, Fairbairn N, Fowler A, Boyd J, Kerr T, McNeil R.   +5 more
europepmc   +1 more source

Desirable treatment or a problematic drug scene? - An interview study of patients' and professionals' views on the risks and benefits of liberalized opioid agonist treatment. [PDF]

Harm Reduct J
Nordgren J, Richert T.
europepmc   +1 more source